Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 2:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 22,255 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: control 2 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Vascepa to Accelerate Lipoprotein Uptake and Elimination

NCT03885661
View directory record Official record
Conditions
Lipid Disorder, Triglycerides High, Dyslipidemias
Interventions
Icosapent Ethyl 1000 MG [Vascepa]
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Nov 12, 2026, 2:59 PM EST
Completed Phase 1 Interventional

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B

NCT01590641
View directory record Official record
Conditions
Hepatitis B, HBV
Interventions
Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Phoenix, Arizona • Costa Mesa, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Nov 12, 2026, 2:59 PM EST
Completed Not applicable Interventional

Proning Early in Awake COVID-19 Hypoxic Respiratory Failure (PREACHR) Study

NCT05130541
View directory record Official record
Conditions
Covid19, Respiratory Failure
Interventions
Proning, Supportive Care
Behavioral · Other
Lead sponsor
New York Hospital Queens
Other
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Flushing, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Nov 12, 2026, 2:59 PM EST
Terminated Phase 3 Interventional

A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes

NCT00449605
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Rimonabant, Glimepiride, Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Nov 12, 2026, 2:59 PM EST
Completed Phase 3 Interventional Results available

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

NCT01183013
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Pioglitazone 15 mg, Pioglitazone 45 mg, Pioglitazone 30 mg, Linagliptin 5mg / Pioglitazone 45 mg FDC, Linagliptin 5mg / Pioglitazone 30 mg FDC, Linagliptin 5mg, Linagliptin 5mg / Pioglitazone 15 mg FDC
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
936 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
74
States / cities
Birmingham, Alabama • Montgomery, Alabama • Muscle Shoals, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Nov 12, 2026, 2:59 PM EST
Not listed Not applicable Interventional

A Comparison of Two Target Mean Arterial Pressures in the Resuscitation of Hypotensive Trauma Patients

NCT00459160
View directory record Official record
Conditions
Hemorrhagic Shock, Trauma, Wounds, Penetrating, Shock, Traumatic, Multiple Trauma
Interventions
Intraoperative Hypotensive Resuscitation
Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 45 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2010 · Synced Nov 12, 2026, 2:59 PM EST
Active, not recruiting Phase 2 Interventional

A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus

NCT07340320
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
CX11, Placebo
Drug · Other
Lead sponsor
Corxel Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
30
States / cities
Birmingham, Alabama • Huntsville, Alabama • Cerritos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 12, 2026, 2:59 PM EST
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors

NCT02100696
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrozulimab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
38
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Nov 12, 2026, 2:59 PM EST
Recruiting Phase 3 Interventional

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

NCT07357727
View directory record Official record
Conditions
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Interventions
Pelabresib, Ruxolitinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
22
States / cities
Denver, Colorado • New Haven, Connecticut • Fort Myers, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 12, 2026, 2:59 PM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

NCT03161483
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
CC-220, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
46
States / cities
Tuscaloosa, Alabama • Mesa, Arizona • Fullerton, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Nov 12, 2026, 2:59 PM EST
Recruiting Phase 2 Interventional

Resilience Enhancement Following Sleep Treatment

NCT07298941
View directory record Official record
Conditions
Chronic Low Back Pain (CLBP), Insomnia
Interventions
Cognitive-behavioral therapy for insomnia (CBTi), CBTi + Savoring Meditation, CBTi + Pain Education
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Nov 12, 2026, 2:59 PM EST
Completed No phase listed Observational

Long-Term Follow Up Study for AMD3100 Patients

NCT00476294
View directory record Official record
Conditions
Myeloma
Interventions
Telephone Questionnaire
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 78 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Nov 12, 2026, 2:59 PM EST
Active, not recruiting No phase listed Observational

Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF

NCT05639556
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
BMI and lean mass index from DXA, Anthropometric Measurements, Hand-grip strength, Six-minute walk Test, Sit-to-Stand Test, Short physical performance battery (SPPB), BIA Sub-study, Accelerometry to assess physical activity, Gastrointestinal (GI) and nutrition questionnaires:, Psychosocial questionnaire: PHQ-8, Psychosocial questionnaire: GAD-7, Psychosocial questionnaire: The Treatment Self-Regulation Questionnaire (TSRQ), Psychosocial questionnaire: CF Fatalism Scale, Psychosocial questionnaire: Body Esteem Scale for Adolescents and Adults (BESAA), 12-month Questionnaire, Oral glucose tolerance testing (OGTT), Continuous glucose monitoring (CGM), Chest CT scans (When available within the past 6 months in medical records), Hologic Dual X-Ray Absorptiometry (DXA), Ultrasound Sub-study of assessment of appendage muscles using ultrasound, Psychosocial questionnaire: Hunger Vital Sign questionnaire, Respiratory symptom questionnaire: CRISS, Spirometry, Psychosocial questionnaire: Additional Health Questionnaire, CF Management Questionnaire, Food Frequency Questionnaire
Diagnostic Test · Other · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
23
States / cities
Tucson, Arizona • Little Rock, Arkansas • Atlanta, Georgia + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Nov 12, 2026, 2:59 PM EST
Completed Phase 3 Interventional Results available

Welchol as Monotherapy for Type 2 Diabetes Mellitus

NCT00789737
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Welchol, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
107
States / cities
Birmingham, Alabama • Montgomery, Alabama • Muscle Shoals, Alabama + 87 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Nov 12, 2026, 2:59 PM EST
Completed Not applicable Interventional Results available

Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery

NCT01245595
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Day to 18 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Nov 12, 2026, 2:59 PM EST
Completed Phase 3 Interventional Results available

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors

NCT01882439
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Tofacitinib, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
43
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Nov 12, 2026, 2:59 PM EST
Completed Not applicable Interventional Results available

Patient-centered Mobile Health Intervention to Improve Self-care in Patients With Chronic Heart Failure

NCT03642275
View directory record Official record
Conditions
Heart Failure
Interventions
iCardia4HF
Behavioral
Lead sponsor
University of Illinois Chicago
Other
Eligibility
40 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Nov 12, 2026, 2:59 PM EST
Not listed Not applicable Interventional

Priming With tDCS: Expanding the Window of Recovery in Chronic Stroke

NCT03964467
View directory record Official record
Conditions
Upper Extremity Paresis
Interventions
transcranial direct current stimulation
Device
Lead sponsor
University of the Sciences in Philadelphia
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Nov 12, 2026, 2:59 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Anesthetic Efficacy of 3% Mepivacaine Plus 2% Lidocaine With 1:100,000 Epinephrine for Lower Jaw Dental Injections

NCT01574807
View directory record Official record
Conditions
Pain
Interventions
mepivacaine + lidocaine followed by lidocaine +lidocaine, lidocaine + lidocaine followed by mepivacaine + lidocaine
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Nov 12, 2026, 2:59 PM EST
Completed Not applicable Interventional

Acceptance and Commitment Therapy, a Mindfulness-Based Approach for Treatment of Chronic Musculoskeletal Pain

NCT04502992
View directory record Official record
Conditions
Chronic Musculoskeletal Disease
Interventions
Acceptance and Committment Therapy
Behavioral
Lead sponsor
University of New Hampshire
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Nov 12, 2026, 2:59 PM EST
Not listed Not applicable Interventional

Decreasing Parental Stress of Caregivers of Infants With Infantile Spasms by Using Telemedicine Technology

NCT04086992
View directory record Official record
Conditions
Infantile Spasms, Non-Intractable
Interventions
Remote monitoring
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
31 Days to 30 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Nov 12, 2026, 2:59 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Role of Contingency Management in Waterpipe Smoking Cessation

NCT02159092
View directory record Official record
Conditions
Waterpipe Smoking
Interventions
Contingency Management
Behavioral
Lead sponsor
Washington State University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Nov 12, 2026, 2:59 PM EST
Completed Not applicable Interventional

Project Fluido: Fluid Watchers

NCT02083744
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
PsychoEducational Support, Usual Care
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Nov 12, 2026, 2:59 PM EST
Not listed Phase 1 Interventional

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

NCT02059564
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
HM11260C, Placebo, Victoza
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
California City, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Nov 12, 2026, 2:59 PM EST